Bridged Proteolysis Targeting Chimera (PROTAC) Enables Degradation of Undruggable Targets is a research paper published in Journal of the American Chemical Society (2022). On theSindex it has a DataRank of 0. It has been cited 133 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
National Cancer Institute
Grant: R01CA218600
National Cancer Institute
Grant: R01CA230854
National Cancer Institute
Grant: R01CA260666
National Cancer Institute
Grant: R01CA268384
National Cancer Institute
Grant: R01CA268519
National Institute of General Medical Sciences
Grant: T32GM062754
NCI NIH HHS
Grant: R01 CA204314
NIH HHS
Grant: S10 OD028504
NCI NIH HHS
Grant: R01 CA240362
NIH HHS
Grant: S10 OD025132
NCI NIH HHS
Grant: T32 CA078207
National Institutes of Health
Grant: 5R01CA268384-04
Discovery of First-in-class WDR5 PROTACs as a Novel Therapeutic Strategy for MLL-rearranged Leukemias
National Institutes of Health
Grant: 5R01CA260666-05
Development of Novel PROTACs Targeting the ENL YEATS Domain for Treating MLL-rearranged Leukemias
National Institutes of Health
Grant: 1S10OD025132-01A1
An AVANCE NEO 600 MHz NMR Spectrometer System for Structural and Chemical Biology
National Institutes of Health
Grant: 5R01CA218600-05
Targeting Lysine Methyltransferases EZH2 and EZH1 for Treating MLL-rearranged Leukemias
National Institutes of Health
Grant: 2T32GM062754-14
Integrated Training in Pharmacological Sciences
National Institutes of Health
Grant: 1S10OD028504-01
An AVANCE NEO 400 MHz NMR Spectrometer for Chemical Biology and Drug Discovery
National Institutes of Health
Grant: 7R01CA268519-03
Dissecting and targeting canonical and non-canonical oncogenic functions of EZH2 in caner
National Institutes of Health
Grant: 3R01CA230854-03S1
(PQ9) Developing EZH2 Degraders for Treating Triple-Negative Breast Cancer
FWCI
8.07
Citation Percentile
1.0%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals